CellEDIT - CRISPR Cell Line Development Workflow
With Our Workflow, We Overcome Cell Line Development Delivery Limitations
We offer a comprehensive, reliable workflow tailored for a variety of genome edits.
Amid advancements in technology and biopharmaceutical research, cell line development has gained prominence, particularly in drug discovery processes such as pathway analysis, target validation, and disease modeling.
For the successful commercialization of your product, an optimized, high-quality cell line development workflow is not just beneficial—it's essential. By outsourcing your cell line development to a specialized partner like Cytosurge, you leverage industry expertise, minimize risks, optimize results, and enhance operational flexibility.
The CellEDIT service introduces a disruptive cell line engineering workflow that delivers precise quantities of CRISPR Cas9 Ribonucleoproteins directly into the nucleus. This targeted approach minimizes the risk of immune response activation and cytosolic degradation, thus significantly enhancing efficiency and precision compared to conventional methods.
Initial phases of our engagement involve rigorous onboarding of your cell line and injection optimization—critical preparatory steps before deploying the CellEDIT workflow. Once we've intimately understood the unique attributes of your cell line, the specialized CellEDIT process begins. Utilizing cutting-edge single-cell transfection technology, we inject CRISPR reagents directly into the nuclei of individual cells.
The workflow concludes only upon successful clone editing, ensuring a highly customized outcome aligned with your specific requirements. Our technology significantly mitigates off-target effects by delivering precise volumes of RNP complexes directly into the nucleus, resulting in the reliable creation of high-quality engineered cell lines with unparalleled precision and control.
Take advantage of CellEDIT's expertise to enhance your research capabilities: in 10 weeks, we create for you, custom and monoclonal knockout cell lines through direct intra-nuclear injection, suited for your project needs.
Vector-free editing by intra-nuclear delivery
Efficient on Hard-to-transfect cells
Minimized Off-Targets
CRISPR Cell Line Development Workflow - Use Cases
Cancer Cell Lines
Discover how
the CellEDIT workflow was used to produce 3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Immortalized Cell Lines
Explore how
the CellEDIT workflow was used to generate 5 monoclonal Hprt knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Multiplexed Cell Lines
Find out how
the CellEDIT workflow boosted the editing efficiency while preserving cell characteristics and functionality in single and multiple KO CHO-K1 clones.
Resources
Deliverables
gRNA design from the CellEDIT experts.
Two edited clones & two Wild Type clones that went through the CellEDIT workflow (1 cryovial per clone).
Full gRNA design report before starting the CellEDIT workflow.
Full final report including sequencing results of both alleles, monoclonality proof, mycoplasma testing.
On demand:
- Additional clones.
- Off-target analysis & Report.
- Additional information useful for further analysis or publication can be also provided on request.
- Extended quality control available on request.
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
CRISPR-Engineered C2C12 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.